A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.

NCT Number	NCT07139873
Lead Sponsor	Dizal Pharmaceuticals
Conditions	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment	250 participants
Start Date	2025-09-08
Primary Completion	2029-01 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2026-06-03